

Prof. Dr. med. Uwe Platzbecker

Head

Medical Clinic and Policlinic of
Hematology, Cell Therapy and Hemostaseology
University Hospital Leipzig
Liebigstr. 22
04103 Leipzig, Germany
Email: uwe.platzbecker@medizin.uni-leipzig.de



Medical training

- Study of Medicine at the Medical Faculty of Technical University of Dresden (- 1996)

Academic development

- MD („summa cum laude“) at the Medical Faculty of Technical University of Dresden (1997)
- Postdoc supported by the Humboldt Foundation (Feodor Lynen Project) at the Fred Hutchinson Cancer Research Center, Seattle, USA (2001 - 2002)
- Habilitation („Privatdozent“) (2006)
- Appointment as Professor of Translational Hematology at the Medical Faculty of Technical University of Dresden (2012 - 2018)
- Appointment as Professor of Hematology at the University of Leipzig (2018 -)

Medical leadership positions

- Senior physician and Head of Hematology outpatient department, Medical Clinic and Policlinic I, University Hospital “Carl Gustav Carus” at the Technical University of Dresden (2005)
- Head of the Hematology section, University Hospital “Carl Gustav Carus” at the Technical University of Dresden (2014 - 2018)
- Chairman of the Medical Ethics Committee of the Technical University of Dresden (2014 - 2018)
- Head of Medical Clinic and Policlinic of Hematology, Cell Therapy and Hemostaseology at the University Hospital in Leipzig (2018 -)

Further scientific activities

- Speaker of German MDS Study Group
- Member of the International MDS Foundation’s Medical & Scientific Advisory Board
- Chairman of the European Myelodysplastic Syndromes Cooperative Group (EMSCO)
- Chairman EHA MDS working party (SWG)
- Board Member of the SAL study group
- Visiting Professor at the Faculty of Life Science and Medicine at King’s College London, UK
- EuroBloodNet coordinator (myeloid malignancies)
- Section Editor *Leukemia*
- Editorial Board *Journal of Clinical Oncology*

Honors

- Chugai Science Award (2006)
- Best abstract, European Leukemia Net meeting (2010)
- 2012 DGHO Poster Award
- Van Bekkum Award of the EBMT in the name of the German MDS Study Group (2019)

Selected publications

Fenaux P, **Platzbecker U**, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Diez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Gotze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstrom-Lindberg E, Zeidan AM, Ades L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *N Engl J Med*, 382(2), 140-151

Platzbecker U. Treatment of MDS. *Blood*. 2019 Mar 7;133(10):1096-1107.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. *Lancet Oncol*. 2018 Dec;19(12):1668-1679.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. *Blood*. 2019 Mar 7;133(10):1020-1030.

Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, **Platzbecker U**. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. *Blood*. 2018 Dec 20;132(25):2629-2638.

Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stölzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhäuser M, Wolf D, Theurl I, **Platzbecker U**. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. *Lancet Haematol*. 2018 May;5(5):e201-e210.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. *J Clin Oncol*. 2017 Feb 20;35(6):605-62.

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. *Lancet Haematol*. 2015 Oct;2(10):e417-26.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, **Platzbecker U**; Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med*. 2013 Jul 11;369(2):111-21.